Table I.
Patient’s treatment, disease activity, control and impact, blood markers, and autologous serum skin test reactivity
| Time | Dupilumab | UAS7 | UCT | CU-QoL | IgE1 | EOS2 | BASO3 | D-dimer4 | ASST |
|---|---|---|---|---|---|---|---|---|---|
| Baseline | ※ | 30/42 | 6/16 | 35 | 34 | NA | NA | NA | NA |
| Wk 1 | 600 mg | 42/42 | 2/16 | NA | NA | 590 | 20 | 0.69 | +++ |
| Wk 3 | 300 mg | 4/42 | 13/16 | NA | NA | NA | NA | NA | + |
| Wk 6 | 300 mg | 4/42 | NA | 3 | NA | 660 | 50 | 0.30 | NA |
| Wk 10 | 300 mg | 2/42 | 14/16 | 2 | 71 | 590 | 50 | NA | NA |
| Wk 16 | 300 mg | 0/42 | 16/16 | 0 | 10 | 570 | 50 | NA | − |
| Wk 20 | ※ | 0/42 | 16/16 | 0 | NA | NA | NA | NA | NA |
| Wk 24 | 300 mg | 0/42 | 16/16 | 0 | 22 | 4620 | 70 | NA | NA |
| Wk 36 | ※ | 0/42 | 16/16 | 0 | NA | 6210 | 130 | NA | NA |
| Wk 37 | ※ | 0/42 | NA | NA | NA | 7930 | 130 | NA | NA |
| Wk 38 | ※ | 0/42 | 16/16 | 0 | NA | 50 | 50 | NA | NA |
| Wk 39 | ※ | 0/42 | NA | NA | NA | NA | NA | NA | NA |
| Wk 42 | ※ | 0/42 | 16/16 | 0 | NA | 460 | 50 | NA | NA |
+++, Strong positive; +, positive; −, negative; ※, not given.
1Total IgE in IU/ml, upper level of normal = 165 IU/ml; 2in cubic millimeters, upper level of normal = 500; 3in cubic millimeters, upper level of normal = 100; 4in mg/L, upper level of normal = 0.256.
ASST, Autologous serum skin test; BASO, basophils; CU-QoL, chronic urticaria quality of life questionnaire; EOS, eosinophils; NA, not assessed; UAS7, Urticaria Activity Score 7; UCT, urticaria control test.